Clinicians are far more cautious using immunotherapy in organ transplant recipients than in patients with autoimmune disease. The risk of irreversible graft rejection is a major deterrent, reserving checkpoint inhibitors only for when no other treatment options exist.

At NYU, bioethicists concluded that limb transplants are often not the best ethical choice. The quality of modern prosthetics has advanced so much that it's preferable to avoid a transplant that would condemn the patient to a lifetime of immunosuppressant drugs and their associated health risks.

When debating immunotherapy risks, clinicians separate manageable side effects from truly life-altering events. Hypothyroidism requiring a daily pill is deemed acceptable, whereas toxicities like diabetes or myocarditis (each ~1% risk) are viewed as major concerns that heavily weigh on the risk-benefit scale for early-stage disease.

Though typically contraindicated, checkpoint inhibitors can be used for transplant recipients with advanced skin cancer. This requires shared decision-making, collaboration with the transplant team, and a specific protocol involving high-dose pulse steroids to mitigate the high risk of allograft rejection.

To mitigate organ rejection risk in transplant patients with CSCC, oncologists should coordinate with transplant teams to switch from drugs like tacrolimus to an mTOR inhibitor. This proactive switch can prevent rejection and may even enhance the immunotherapy's effectiveness.

Memo Therapeutics CEO Erik van den Berg explains the BK virus, dormant in 90% of the population, reactivates under severe immunosuppression required for organ transplants. This doubles the risk of kidney graft failure and triples the risk of death for these patients, who currently have no available treatment.

Using checkpoint inhibitors in renal transplant recipients requires extreme caution due to a significant risk of graft rejection, potentially leading to dialysis. This decision is a major trade-off and must involve a case-by-case discussion with the patient and a nephrologist.

Erik van den Berg highlights a critical paradox in the current standard of care for BK virus infections post-transplant. The only available intervention is lowering immunosuppression to fight the virus, but this simultaneously increases the probability that the patient's immune system will reject the newly transplanted organ.

When counseling transplant patients about immunotherapy for CSCC, clinicians can cite retrospective data indicating a roughly 33% chance of organ rejection and a 20% chance of complete organ loss. This provides a clear, quantitative framework for informed consent and shared decision-making.